CD44 was found to critically contribute to activating the oncogenic KRAS signalling pathway through the MAPK pathway in lung adenocarcinoma cell lines, hence promoting tumour cell proliferation and survival [58]. Here, CD44 is linked to lung adenocarcinoma.